Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML

Kyriaki Dunussi-Joannopoulos, Howard J. Weinstein, Peter W. Nickerson, Terry B. Strom, Steven J. Burakoff, James Croop, Robert J. Arceci

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Recent studies have shown that tumor cells genetically modified by transduction of B7-1, a natural ligand for the T-cell costimulatory molecules CD28 and CTLA-4, are rejected in syngeneic hosts. In these reports, transformed cell lines and drug-selected cells have been used for vaccinations. To determine the effectiveness of B7-1-transduced primary acute myelogenous leukemia (AML) cells on the induction of antitumor immunity, we have studied a murine AML model in which primary AML cells were retrovirally transduced with the murine B7-1 cDNA. A defective retroviral producer clone expressing B7-1 and secreting a high titer of virus was used for infection of AML cells. Unselected transduced AML cells, expressing a high level of B7-1, were used for in vivo vaccinations. Our results show that one intravenous (IV) injection of irradiated B7-1-positive (B7-1+) AML cells can provide long-lasting (5 to 6 months) systemic immunity against subsequent challenge with wild-type AML cells. Furthermore, one exposure to irradiated B7-1+ AML cells results in rejection of leukemia by leukemic mice when the vaccination occurs in the early stages of the disease. The antileukemia immunity is CD8+ T-cell-dependent and B7/CD28-mediated, since in vivo treatment of mice with anti-CD8 monoclonal antibody or CTLA-4 Ig leads to abrogation of the specific antileukemia immune response. These results emphasize that B7-1 vaccines may have therapeutic usefulness for patients with AML.

Original languageEnglish (US)
Pages (from-to)2938-2946
Number of pages9
JournalBlood
Volume87
Issue number7
StatePublished - Apr 1 1996
Externally publishedYes

Fingerprint

T-cells
Acute Myeloid Leukemia
Vaccines
Cells
Viruses
Tumors
Complementary DNA
Monoclonal Antibodies
Ligands
Molecules
Immunity
Vaccination
Therapeutics
Pharmaceutical Preparations
T-Lymphocytes
Transformed Cell Line
Viral Load
Intravenous Injections
Leukemia
Clone Cells

ASJC Scopus subject areas

  • Hematology

Cite this

Dunussi-Joannopoulos, K., Weinstein, H. J., Nickerson, P. W., Strom, T. B., Burakoff, S. J., Croop, J., & Arceci, R. J. (1996). Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood, 87(7), 2938-2946.

Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. / Dunussi-Joannopoulos, Kyriaki; Weinstein, Howard J.; Nickerson, Peter W.; Strom, Terry B.; Burakoff, Steven J.; Croop, James; Arceci, Robert J.

In: Blood, Vol. 87, No. 7, 01.04.1996, p. 2938-2946.

Research output: Contribution to journalArticle

Dunussi-Joannopoulos, K, Weinstein, HJ, Nickerson, PW, Strom, TB, Burakoff, SJ, Croop, J & Arceci, RJ 1996, 'Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML', Blood, vol. 87, no. 7, pp. 2938-2946.
Dunussi-Joannopoulos K, Weinstein HJ, Nickerson PW, Strom TB, Burakoff SJ, Croop J et al. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood. 1996 Apr 1;87(7):2938-2946.
Dunussi-Joannopoulos, Kyriaki ; Weinstein, Howard J. ; Nickerson, Peter W. ; Strom, Terry B. ; Burakoff, Steven J. ; Croop, James ; Arceci, Robert J. / Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. In: Blood. 1996 ; Vol. 87, No. 7. pp. 2938-2946.
@article{688ad8340e4542579cb1eb726d90d9d8,
title = "Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML",
abstract = "Recent studies have shown that tumor cells genetically modified by transduction of B7-1, a natural ligand for the T-cell costimulatory molecules CD28 and CTLA-4, are rejected in syngeneic hosts. In these reports, transformed cell lines and drug-selected cells have been used for vaccinations. To determine the effectiveness of B7-1-transduced primary acute myelogenous leukemia (AML) cells on the induction of antitumor immunity, we have studied a murine AML model in which primary AML cells were retrovirally transduced with the murine B7-1 cDNA. A defective retroviral producer clone expressing B7-1 and secreting a high titer of virus was used for infection of AML cells. Unselected transduced AML cells, expressing a high level of B7-1, were used for in vivo vaccinations. Our results show that one intravenous (IV) injection of irradiated B7-1-positive (B7-1+) AML cells can provide long-lasting (5 to 6 months) systemic immunity against subsequent challenge with wild-type AML cells. Furthermore, one exposure to irradiated B7-1+ AML cells results in rejection of leukemia by leukemic mice when the vaccination occurs in the early stages of the disease. The antileukemia immunity is CD8+ T-cell-dependent and B7/CD28-mediated, since in vivo treatment of mice with anti-CD8 monoclonal antibody or CTLA-4 Ig leads to abrogation of the specific antileukemia immune response. These results emphasize that B7-1 vaccines may have therapeutic usefulness for patients with AML.",
author = "Kyriaki Dunussi-Joannopoulos and Weinstein, {Howard J.} and Nickerson, {Peter W.} and Strom, {Terry B.} and Burakoff, {Steven J.} and James Croop and Arceci, {Robert J.}",
year = "1996",
month = "4",
day = "1",
language = "English (US)",
volume = "87",
pages = "2938--2946",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML

AU - Dunussi-Joannopoulos, Kyriaki

AU - Weinstein, Howard J.

AU - Nickerson, Peter W.

AU - Strom, Terry B.

AU - Burakoff, Steven J.

AU - Croop, James

AU - Arceci, Robert J.

PY - 1996/4/1

Y1 - 1996/4/1

N2 - Recent studies have shown that tumor cells genetically modified by transduction of B7-1, a natural ligand for the T-cell costimulatory molecules CD28 and CTLA-4, are rejected in syngeneic hosts. In these reports, transformed cell lines and drug-selected cells have been used for vaccinations. To determine the effectiveness of B7-1-transduced primary acute myelogenous leukemia (AML) cells on the induction of antitumor immunity, we have studied a murine AML model in which primary AML cells were retrovirally transduced with the murine B7-1 cDNA. A defective retroviral producer clone expressing B7-1 and secreting a high titer of virus was used for infection of AML cells. Unselected transduced AML cells, expressing a high level of B7-1, were used for in vivo vaccinations. Our results show that one intravenous (IV) injection of irradiated B7-1-positive (B7-1+) AML cells can provide long-lasting (5 to 6 months) systemic immunity against subsequent challenge with wild-type AML cells. Furthermore, one exposure to irradiated B7-1+ AML cells results in rejection of leukemia by leukemic mice when the vaccination occurs in the early stages of the disease. The antileukemia immunity is CD8+ T-cell-dependent and B7/CD28-mediated, since in vivo treatment of mice with anti-CD8 monoclonal antibody or CTLA-4 Ig leads to abrogation of the specific antileukemia immune response. These results emphasize that B7-1 vaccines may have therapeutic usefulness for patients with AML.

AB - Recent studies have shown that tumor cells genetically modified by transduction of B7-1, a natural ligand for the T-cell costimulatory molecules CD28 and CTLA-4, are rejected in syngeneic hosts. In these reports, transformed cell lines and drug-selected cells have been used for vaccinations. To determine the effectiveness of B7-1-transduced primary acute myelogenous leukemia (AML) cells on the induction of antitumor immunity, we have studied a murine AML model in which primary AML cells were retrovirally transduced with the murine B7-1 cDNA. A defective retroviral producer clone expressing B7-1 and secreting a high titer of virus was used for infection of AML cells. Unselected transduced AML cells, expressing a high level of B7-1, were used for in vivo vaccinations. Our results show that one intravenous (IV) injection of irradiated B7-1-positive (B7-1+) AML cells can provide long-lasting (5 to 6 months) systemic immunity against subsequent challenge with wild-type AML cells. Furthermore, one exposure to irradiated B7-1+ AML cells results in rejection of leukemia by leukemic mice when the vaccination occurs in the early stages of the disease. The antileukemia immunity is CD8+ T-cell-dependent and B7/CD28-mediated, since in vivo treatment of mice with anti-CD8 monoclonal antibody or CTLA-4 Ig leads to abrogation of the specific antileukemia immune response. These results emphasize that B7-1 vaccines may have therapeutic usefulness for patients with AML.

UR - http://www.scopus.com/inward/record.url?scp=0029878206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029878206&partnerID=8YFLogxK

M3 - Article

VL - 87

SP - 2938

EP - 2946

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -